Medexcel Impex Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 02-07-2024
- Paid Up Capital ₹ 0.10 M
as on 02-07-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
as on 02-07-2024
- Revenue -84.47%
(FY 2022)
- Profit -65.34%
(FY 2022)
- Ebitda 1379.43%
(FY 2022)
- Net Worth 0.96%
(FY 2022)
- Total Assets -5.56%
(FY 2022)
About Medexcel Impex
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Renuka Bala and Kamal Rustagi serve as directors at the Company.
- CIN/LLPIN
U51397DL2016PTC303513
- Company No.
303513
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jul 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Medexcel Impex Private Limited offer?
Medexcel Impex Private Limited offers a wide range of products and services, including Weighing Scales & Measuring Tapes, Measuring Ruler, Weighing Scale, Electronic Weighing Scales, Pulse Oximeter, Glucometer & POCT Devices, Blood Pressure Machine, Balancing Machines, Calipers, Food Weighing Machine, Surgical & ICU Equipments.
Who are the key members and board of directors at Medexcel Impex?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Renuka Bala  | Director | 25-Jul-2016 | Current |
| Kamal Rustagi | Director | 25-Jul-2016 | Current |
Financial Performance of Medexcel Impex.
Medexcel Impex Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 84.47% decrease. The company also saw a substantial fall in profitability, with a 65.34% decrease in profit. The company's net worth moved up by a moderate rise of 0.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medexcel Impex?
In 2021, Medexcel Impex had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 27 Sep 2023 | ₹1.00 M | Open |
How Many Employees Work at Medexcel Impex?
Unlock and access historical data on people associated with Medexcel Impex, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medexcel Impex, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medexcel Impex's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
